Mechanism of Treatment Resistance in Human Glioblastoma
Timothy A. Johnson Medical Scholar Lecture presented by the Fralin Biomedical Research Institute at VTC and the Virginia Tech Carilion School of Medicine
Archived Lecture: Mechanism of Treatment Resistance in Human Glioblastoma
Date: April 16, 2021
Time: 1:00 p.m. - 2:00 p.m.
About this Lecture
The standard therapy for Glioblastoma (GBM), the most lethal primary brain tumor, has been surgical resection followed by chemoradiation and adjuvant temozolomide (TMZ). However, the survival of patients with GBM remains unacceptably low at 16-18 months, with little improvement over the last 20 years. This is due to a high level of resistance to therapy attributing to tumor heterogeneity, and intrinsic tumor cell resistance and tumor environment suppression. The cytotoxicity of TMZ is mediated by its addition of methyl groups at N7 and O6 sites on guanines and the O3 site on adenines in genomic DNA. In approximately 60% of patients, O6-methylguanine (O6-MetG) is rapidly removed by O6-methylguanine-DNA methyltransferase (MGMT), conferring resistance to TMZ chemotherapy. Thus, inhibition of TMZ-induced DNA damage repair represents an attractive strategy for potentiating the activity of TMZ. Poly-ADP-ribose polymerase (PARP) is critical for regulating a variety of DNA damage repair mechanisms such as BER/SSBR, and PARP inhibitors have been shown to have single agent activity in breast and ovarian cancer patients with BRCA ½ mutations. Dr. Yung's lab has been studying the function of several PARP inhibitors. The lab first observed EGFR amplification is a marker of single agent activity with PARP/DNA complex trapping PARP inhibitors like Telazoparib, olaparib and pamiparib. Interestingly, the researchers also found that PARP binds to MGMT, and this binding is increased by TMZ treatment. The lab further observed that PARP binding leads to poly(ADP-ribosyl)ation (PARylation) of MGMT which is necessary for MGMT removal O6-methylguanine lesions in damaged DNA; and that PARP inhibitors reverse this action and inhibit MGMT removal of O6-MetG. Combination experiments of TMZ and PARP inhibitors showed increased DSB as shown by H2AX and 53P1 foci formation. Combination of TMZ and PARP inhibitor also significantly inhibited tumor growth and increase survival in animals. In summary, Yung and his lab have discovered a unique function of PARP inhibitor in reversing tumor resistance to TMZ chemotherapy in patients with MGMT unmethylated GBM: blocking BER/SSBR pathway to repair TMZ induced N7-Met and O3-MetA, and more importantly, suppressing MGMT activity to repair O6-MetG, resulting in augmented TMZ cytotoxicity. The lab also demonstrated EGFR amplification could serve as a biomarker for PARP inhibitor activity. Based on these data, Yung's lab is planning clinical trials to test the combination of TMZ and a brain penetrant PARP inhibitors in MGMT unmethylated GBM.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and the Virginia Tech Carilion School of Medicine. The Timothy A. Johnson Medical Scholar Lecture Series hosts clinician scientists who are exploring frontiers of medicine. These lectures are principally intended for Virginia Tech Carilion School of Medicine students and Virginia Tech students in Translational Biology, Medicine, and Health graduate program. Virginia Tech and Carilion Clinic faculty, staff, and students may also attend.
You May Also Be Interested In...
-
Home ItemThe Bitter Truth: Alcohol Use and Its Effects on Chemosensory Function , home
Oct. 3, 2025, 11:00 a.m. | Paule Valery Joseph, Ph.D., Lasker Clinical Research Scholar, NIH Distinguished Scholar; Acting Chief, Section of Sensory Science and Metabolism Unit, Co-Director of the National Smell and Taste Center, National Institute on Deafness and Other Communication Disorders; National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health | Co-Sponsored by the Fralin Biomedical Research Institute Center for Health Behaviors Research and Addiction Recovery Research Center
-
Home ItemOrganization and Control of Hippocampal Networks , home
Oct. 17, 2025, 11:00 a.m. | Ivan Soltesz, Ph.D., James R. Doty Professor of Neurosurgery and Neurosciences, Stanford University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Neurobiology Research
-
Home ItemMaury Strauss Distinguished Public Lecture , home
Oct. 30, 2025, 5:30 p.m. (Reception at 5 p.m.) | Jennifer Munson, Ph.D., Professor and Director, Cancer Research Center — Roanoke, Fralin Biomedical Research Institute; Professor, Department of Biomedical Engineering and Mechanics, Virginia Tech College of Engineering | Maury Strauss Distinguished Public Lecture
-
Home ItemThinking the Right Thoughts , home
Oct. 31, 2025, 11 a.m. | Nathaniel Daw, Ph.D., Professor, Computational and Theoretical Neuroscience, Department of Psychology, Princeton University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home ItemMaury Strauss Distinguished Public Lecture , home
Nov. 6, 2025, 5:30 p.m. (Reception at 5 p.m.) | Teresa Lambe, Ph.D., OBE, Calleva Head of Vaccine Immunology, Professor of Vaccinology and Immunology, University of Oxford | Maury Strauss Distinguished Public Lecture

W.K. Alfred Yung, M.D.
Professor, Department of Neuro-Oncology, Division of Cancer Medicine; Senior Advisor, Brain Tumor Center; Moonshot Executive Committee Member, The University of Texas MD Anderson Cancer Center